Aspire Biopharma Holdings, Inc. (ASBP): Nasdaq/NYSE listing notice — Aspire Biopharma receives Nasdaq delisting notices for MVLS below $50M and bid price under $1.00

Aspire Biopharma Holdings, Inc.

Received two letters on April 16, 2025: MVLS deficiency (below $50M for 30 consecutive days) and bid price deficiency (below $1.00).
Company has 180 days until October 13, 2025 to regain compliance with MVLS; must achieve at least $50M for 10 consecutive business days.
Bid Price Rule allows 180-day compliance period; failure may lead to delisting or transfer to Nasdaq Capital Market.
Company is evaluating potential responses but has not decided on actions; no assurance of regaining compliance.
Tickers affected: ASBP (common stock) and ASBPW (warrants), both on Nasdaq Global Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aspire Biopharma Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

April 16, 2025, Aspire Biopharma Holdings, Inc. (the “Company”), received two letters from the Nasdaq Stock Exchange LLC (“Nasdaq”), each addressing a separate compliance deficiency under the Nasdaq Listing Rules. The first letter notified of the deficiency with regard to Rule 5450(b)(2)(A) (the “MVLS Notice”), which requires a company, whose securities are listed on The Nasdaq Global Market under the “Market Value Standard”, to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000. The deficiency was caused by the Company’s MVLS having been below the minimum level fo

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aspire Biopharma Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5810(c)(3)(C)

Exact text from the filing

April 16, 2025, Aspire Biopharma Holdings, Inc. (the “Company”), received two letters from the Nasdaq Stock Exchange LLC (“Nasdaq”), each addressing a separate compliance deficiency under the Nasdaq Listing Rules. The first letter notified of the deficiency with regard to Rule 5450(b)(2)(A) (the “MVLS Notice”), which requires a company, whose securities are listed on The Nasdaq Global Market under the “Market Value Standard”, to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000. The deficiency was caused by the Company’s MVLS having been below the minimum level fo

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Aspire Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-005427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.